STP06 1002

Drug Profile

STP06 1002

Alternative Names: STP06-1002

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator Korea Research Institute of Chemical Technology; ST Pharm
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Tankyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Colorectal cancer in South Korea (PO) before April 2017
  • 01 Apr 2017 ST Pharm has patents pending for STP06 1002 in Colorectal cancer
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top